Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.29 USD

1.29
653,771

+0.01 (0.78%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.28 -0.01 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks

by Zacks Equity Research

ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.

Zacks Equity Research

Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 0% and 3.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 7.41% and 3.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Accuray Stock in Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Accuray Stock in Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan

by Zacks Equity Research

The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.

Zacks Equity Research

Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care

by Zacks Equity Research

ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.

Zacks Equity Research

Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US

by Zacks Equity Research

Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.

Zacks Equity Research

Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks

by Zacks Equity Research

Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Zacks Equity Research

Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments

by Zacks Equity Research

Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.

Zacks Equity Research

Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA

by Zacks Equity Research

Accuray (ARAY) announces the approval of the Accuray Precision Treatment Planning System by the Chinese Medical Products Administration.

Zacks Equity Research

Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for May 31st

by Zacks Equity Research

ASGN, ARAY and BGS have been added to the Zacks Rank #5 (Strong Sell) List on May 31, 2023.

Zacks Equity Research

New Strong Sell Stocks for May 24th

by Zacks Equity Research

DDD, ARAY and BNTGY have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2023.

Zacks Equity Research

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

by Zacks Equity Research

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

Zacks Equity Research

Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -500% and 11.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

What's in Store for These 4 Medical Device Stocks in Q1 Earnings?

by Indrajit Bandyopadhyay

Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.

Zacks Equity Research

Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inari Medical (NARI) delivered earnings and revenue surprises of -136.36% and 3.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Can the 4 Medical Device Stocks Hit Targets This Earnings Season?

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.

Zacks Equity Research

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

by Zacks Equity Research

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Zacks Equity Research

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

by Zacks Equity Research

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

Zacks Equity Research

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.